COGT
Cogent Biosciences, Inc.
Price Chart
No historical data available
Latest Quote
$30.91
-0.30 (-0.96%)
Current Price
| Previous Close | $31.21 |
| Open | $31.22 |
| Day High | $31.50 |
| Day Low | $30.52 |
| Volume | 2,205,980 |
Stock Information
| Shares Outstanding | 173.52M |
| Total Debt | $244.26M |
| Cash Equivalents | $792.30M |
| Net Income | $-377.18M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.36B |
| EPS (TTM) | $-2.16 |
| Exchange | NMS |
Recent Price History
No history data available. Data will be fetched automatically.
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
đ° Latest News
No news articles available at the moment. Check back later for updates on COGT.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $3,062,000 | $0 | $0 | - |
| Total Expenses | $333,363,000 | $275,939,000 | $208,130,000 | $147,839,000 |
| Other Income Expense | $-7,201,000 | $1,992,000 | $2,643,000 | $3,609,000 |
| Other Non Operating Income Expenses | $-20,000 | $1,992,000 | $2,643,000 | $3,609,000 |
| Net Non Operating Interest Income Expense | $11,627,000 | $18,088,000 | $13,077,000 | $3,989,000 |
| Interest Expense Non Operating | $3,062,000 | $0 | $0 | - |
| Operating Expense | $333,363,000 | $275,939,000 | $208,130,000 | $147,839,000 |
| General And Administrative Expense | $63,583,000 | $43,281,000 | $34,375,000 | $26,212,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-328,937,000 | $-255,859,000 | $-192,410,000 | $-140,241,000 |
| Net Interest Income | $11,627,000 | $18,088,000 | $13,077,000 | $3,989,000 |
| Interest Income | $14,689,000 | $18,088,000 | $13,077,000 | $3,989,000 |
| Normalized Income | $-321,756,000 | $-255,859,000 | $-192,410,000 | $-140,241,000 |
| Net Income From Continuing And Discontinued Operation | $-328,937,000 | $-255,859,000 | $-192,410,000 | $-140,241,000 |
| Total Operating Income As Reported | $-333,363,000 | $-275,939,000 | $-208,130,000 | $-147,839,000 |
| Net Income Common Stockholders | $-328,937,000 | $-255,859,000 | $-192,410,000 | $-140,241,000 |
| Net Income | $-328,937,000 | $-255,859,000 | $-192,410,000 | $-140,241,000 |
| Net Income Including Noncontrolling Interests | $-328,937,000 | $-255,859,000 | $-192,410,000 | $-140,241,000 |
| Net Income Continuous Operations | $-328,937,000 | $-255,859,000 | $-192,410,000 | $-140,241,000 |
| Pretax Income | $-328,937,000 | $-255,859,000 | $-192,410,000 | $-140,241,000 |
| Special Income Charges | $-7,181,000 | $0 | $0 | - |
| Interest Income Non Operating | $14,689,000 | $18,088,000 | $13,077,000 | $3,989,000 |
| Operating Income | $-333,363,000 | $-275,939,000 | $-208,130,000 | $-147,839,000 |
| Per Share | ||||
| Diluted EPS | $-2.04 | $-2.32 | $-2.42 | $-2.39 |
| Basic EPS | $-2.04 | $-2.32 | $-2.42 | $-2.39 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-314,111,000 | $-251,508,000 | $-188,822,000 | $-141,961,000 |
| Total Unusual Items | $-7,181,000 | $0 | $0 | - |
| Total Unusual Items Excluding Goodwill | $-7,181,000 | $0 | $0 | - |
| Reconciled Depreciation | $4,583,000 | $4,351,000 | $3,588,000 | $5,878,000 |
| EBITDA (Bullshit earnings) | $-321,292,000 | $-251,508,000 | $-188,822,000 | $-141,961,000 |
| EBIT | $-325,875,000 | $-255,859,000 | $-192,410,000 | $-147,839,000 |
| Diluted Average Shares | $160,980,024 | $110,461,729 | $79,657,942 | $58,739,713 |
| Basic Average Shares | $160,980,024 | $110,461,729 | $79,657,942 | $58,739,713 |
| Diluted NI Availto Com Stockholders | $-328,937,000 | $-255,859,000 | $-192,410,000 | $-140,241,000 |
| Other Special Charges | $7,181,000 | - | - | - |
| Research And Development | $269,780,000 | $232,658,000 | $173,755,000 | $121,627,000 |
| Selling General And Administration | $63,583,000 | $43,281,000 | $34,375,000 | $26,212,000 |
| Other Gand A | $63,583,000 | $43,281,000 | $34,375,000 | $26,212,000 |
| Gain On Sale Of Ppe | - | - | - | - |
Fetched: 2026-10-26
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $636,371,000 | $256,286,000 | $257,802,000 | $255,735,000 |
| Total Assets | $937,607,000 | $327,898,000 | $313,437,000 | $300,810,000 |
| Total Non Current Assets | $27,252,000 | $31,426,000 | $42,666,000 | $35,844,000 |
| Other Non Current Assets | $3,717,000 | $4,862,000 | $4,864,000 | $4,745,000 |
| Current Assets | $910,355,000 | $296,472,000 | $270,771,000 | $264,966,000 |
| Other Current Assets | $9,590,000 | $9,395,000 | $5,061,000 | $4,435,000 |
| Cash Cash Equivalents And Short Term Investments | $900,765,000 | $287,077,000 | $265,710,000 | $259,276,000 |
| Cash And Cash Equivalents | $312,012,000 | $98,165,000 | $53,229,000 | $139,886,000 |
| Investmentin Financial Assets | - | $0 | $7,460,000 | $0 |
| Restricted Cash | - | - | $0 | $1,255,000 |
| Prepaid Assets | - | - | - | $4,435,000 |
| Debt | ||||
| Total Debt | $238,797,000 | $17,467,000 | $18,853,000 | $19,649,000 |
| Long Term Debt And Capital Lease Obligation | $237,250,000 | $15,902,000 | $17,467,000 | $18,226,000 |
| Long Term Debt | $222,895,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $1,547,000 | $1,565,000 | $1,386,000 | $1,423,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $301,236,000 | $71,612,000 | $55,635,000 | $45,075,000 |
| Total Non Current Liabilities Net Minority Interest | $237,283,000 | $15,902,000 | $17,467,000 | $18,226,000 |
| Other Non Current Liabilities | $33,000 | - | - | - |
| Current Liabilities | $63,953,000 | $55,710,000 | $38,168,000 | $26,849,000 |
| Other Current Liabilities | $6,745,000 | $373,000 | $441,000 | $2,104,000 |
| Payables And Accrued Expenses | $39,921,000 | $41,513,000 | $26,467,000 | $17,259,000 |
| Payables | $9,504,000 | $12,013,000 | $10,655,000 | $5,842,000 |
| Accounts Payable | $9,504,000 | $12,013,000 | $10,655,000 | $5,842,000 |
| Current Deferred Liabilities | - | - | - | $1,700,000 |
| Equity | ||||
| Common Stock Equity | $546,978,000 | $145,686,000 | $197,767,000 | $189,905,000 |
| Preferred Stock Equity | $89,393,000 | $110,600,000 | $60,035,000 | $65,830,000 |
| Total Equity Gross Minority Interest | $636,371,000 | $256,286,000 | $257,802,000 | $255,735,000 |
| Stockholders Equity | $636,371,000 | $256,286,000 | $257,802,000 | $255,735,000 |
| Gains Losses Not Affecting Retained Earnings | $355,000 | $447,000 | $246,000 | $-104,000 |
| Other Equity Adjustments | $355,000 | $447,000 | $246,000 | $-104,000 |
| Retained Earnings | $-1,188,420,000 | $-859,483,000 | $-603,624,000 | $-411,214,000 |
| Other | ||||
| Ordinary Shares Number | $160,980,024 | $110,461,729 | $86,124,249 | $69,893,434 |
| Share Issued | $160,980,024 | $110,461,729 | $86,124,249 | $69,893,434 |
| Tangible Book Value | $546,978,000 | $145,686,000 | $197,767,000 | $189,905,000 |
| Invested Capital | $769,873,000 | $145,686,000 | $197,767,000 | $189,905,000 |
| Working Capital | $846,402,000 | $240,762,000 | $232,603,000 | $238,117,000 |
| Capital Lease Obligations | $15,902,000 | $17,467,000 | $18,853,000 | $19,649,000 |
| Total Capitalization | $859,266,000 | $256,286,000 | $257,802,000 | $255,735,000 |
| Additional Paid In Capital | $1,734,882,000 | $1,004,612,000 | $801,059,000 | $601,153,000 |
| Capital Stock | $89,554,000 | $110,710,000 | $60,121,000 | $65,900,000 |
| Common Stock | $161,000 | $110,000 | $86,000 | $70,000 |
| Preferred Stock | $89,393,000 | $110,600,000 | $60,035,000 | $65,830,000 |
| Long Term Capital Lease Obligation | $14,355,000 | $15,902,000 | $17,467,000 | $18,226,000 |
| Current Capital Lease Obligation | $1,547,000 | $1,565,000 | $1,386,000 | $1,423,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $15,740,000 | $12,259,000 | $9,874,000 | $6,063,000 |
| Current Accrued Expenses | $30,417,000 | $29,500,000 | $15,812,000 | $11,417,000 |
| Net PPE | $23,535,000 | $26,564,000 | $30,342,000 | $31,099,000 |
| Accumulated Depreciation | $-8,679,000 | $-6,115,000 | $-3,665,000 | $-1,401,000 |
| Gross PPE | $32,214,000 | $32,679,000 | $34,007,000 | $32,500,000 |
| Leases | $2,463,000 | $2,463,000 | $2,438,000 | $1,776,000 |
| Construction In Progress | $763,000 | $41,000 | $27,000 | $482,000 |
| Other Properties | $8,847,000 | $8,083,000 | $7,635,000 | $5,507,000 |
| Machinery Furniture Equipment | $2,063,000 | $1,995,000 | $1,909,000 | $1,419,000 |
| Buildings And Improvements | $18,078,000 | $20,097,000 | $21,998,000 | $23,316,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $588,753,000 | $188,912,000 | $212,481,000 | $119,390,000 |
| Investments And Advances | - | $0 | $7,460,000 | $0 |
| Available For Sale Securities | - | - | $7,460,000 | - |
| Current Deferred Revenue | - | - | - | $1,700,000 |
Fetched: 2026-10-26
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-265,998,000 | $-208,364,000 | $-156,420,000 | $-125,501,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-264,444,000 | $-207,791,000 | $-153,624,000 | $-118,638,000 |
| Cash Flow From Continuing Operating Activities | $-264,444,000 | $-207,791,000 | $-153,624,000 | $-118,638,000 |
| Operating Gains Losses | $7,181,000 | - | $8,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,554,000 | $-573,000 | $-2,796,000 | $-6,863,000 |
| Investing Cash Flow | $-399,526,000 | $38,276,000 | $-97,824,000 | $-124,718,000 |
| Cash Flow From Continuing Investing Activities | $-399,526,000 | $38,276,000 | $-97,824,000 | $-124,718,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $159,323,000 | $213,336,000 | $161,819,000 | $161,945,000 |
| Financing Cash Flow | $878,233,000 | $214,451,000 | $163,536,000 | $163,558,000 |
| Cash Flow From Continuing Financing Activities | $878,233,000 | $214,451,000 | $163,536,000 | $163,558,000 |
| Net Other Financing Charges | $-51,518,000 | - | - | - |
| Net Common Stock Issuance | $159,323,000 | $213,336,000 | $161,819,000 | $161,945,000 |
| Common Stock Issuance | $159,323,000 | $213,336,000 | $161,819,000 | $161,945,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-54,635,000 | $0 | $0 | - |
| Issuance Of Debt | $272,391,000 | $0 | $0 | - |
| Interest Paid Supplemental Data | $2,015,000 | $0 | - | - |
| End Cash Position | $312,428,000 | $98,165,000 | $53,229,000 | $141,141,000 |
| Beginning Cash Position | $98,165,000 | $53,229,000 | $141,141,000 | $220,939,000 |
| Changes In Cash | $214,263,000 | $44,936,000 | $-87,912,000 | $-79,798,000 |
| Proceeds From Stock Option Exercised | $552,672,000 | $1,115,000 | $1,717,000 | $1,613,000 |
| Net Issuance Payments Of Debt | $217,756,000 | $0 | $0 | - |
| Net Short Term Debt Issuance | $223,100,000 | $0 | $0 | - |
| Short Term Debt Issuance | $223,100,000 | $0 | $0 | - |
| Net Long Term Debt Issuance | $-5,344,000 | $0 | $0 | - |
| Long Term Debt Payments | $-54,635,000 | $0 | $0 | - |
| Long Term Debt Issuance | $49,291,000 | $0 | $0 | - |
| Net Investment Purchase And Sale | $-397,972,000 | $38,849,000 | $-95,028,000 | $-117,855,000 |
| Sale Of Investment | $289,199,000 | $294,452,000 | $253,775,000 | $60,000,000 |
| Purchase Of Investment | $-687,171,000 | $-255,603,000 | $-348,803,000 | $-177,855,000 |
| Net PPE Purchase And Sale | $-1,554,000 | $-573,000 | $-2,796,000 | $-6,863,000 |
| Purchase Of PPE | $-1,554,000 | $-573,000 | $-2,796,000 | $-6,863,000 |
| Change In Working Capital | $8,011,000 | $11,596,000 | $11,442,000 | $751,000 |
| Change In Other Current Liabilities | $-1,532,000 | $-1,386,000 | $-796,000 | $-8,690,000 |
| Change In Other Current Assets | $1,561,000 | $2,000 | $-119,000 | $-1,018,000 |
| Change In Payables And Accrued Expense | $8,177,000 | $17,314,000 | $12,983,000 | $11,945,000 |
| Change In Accrued Expense | $10,686,000 | $15,956,000 | $8,170,000 | $9,586,000 |
| Change In Payable | $-2,509,000 | $1,358,000 | $4,813,000 | $2,359,000 |
| Change In Account Payable | $-2,509,000 | $1,358,000 | $4,813,000 | $2,359,000 |
| Change In Prepaid Assets | $-195,000 | $-4,334,000 | $-626,000 | $-1,486,000 |
| Other Non Cash Items | $601,000 | - | $-1,700,000 | $-1,360,000 |
| Stock Based Compensation | $46,079,000 | $39,740,000 | $30,621,000 | $18,368,000 |
| Amortization Of Securities | $-1,962,000 | $-7,619,000 | $-5,173,000 | $-1,638,000 |
| Depreciation Amortization Depletion | $4,583,000 | $4,351,000 | $3,588,000 | $5,878,000 |
| Depreciation And Amortization | $4,583,000 | $4,351,000 | $3,588,000 | $5,878,000 |
| Depreciation | $4,583,000 | $4,351,000 | $3,588,000 | $5,878,000 |
| Gain Loss On Sale Of PPE | $0 | $0 | $8,000 | $0 |
| Net Income From Continuing Operations | $-328,937,000 | $-255,859,000 | $-192,410,000 | $-140,241,000 |
| Asset Impairment Charge | - | $0 | $0 | $-396,000 |
| Sale Of PPE | - | - | - | - |
| Change In Receivables | - | - | - | - |
| Changes In Account Receivables | - | - | - | - |
Fetched: 2026-10-26